News
Boehringer Ingelheim and Click Therapeutics initiate clinical trial on PDTx treatment for schizophrenia and Akili's EndeavorRx shows promise for adults with ADHD.
Simon-Kucher's Jan Bordon and Kay Schultze discuss how to encourage uptake for digital health products.
Also, Startoon has obtained a US FDA clearance for its wearable recovery tracking device.
Also, Coviu and Alcidion have integrated their remote patient monitoring solutions.
The company reported a larger net loss in the first quarter that included a $330.3 million noncash goodwill impairment charge.
Diabetes management company Hygieia extended its Series B round, and Autonomize AI, a workflow platform for healthcare and life sciences, also announced funding.
The company also laid off workers in the U.K. and Israel as it shifts focus to the U.S. market.
The company reported $33.3 million in revenue for Q1 2023 and a net loss of $8.8 million.
The startup plans to file with the FDA to add other monitoring abilities and to introduce the product later this year.
Users will have the option to participate in groups and schedule a coaching session.